Clinical study on camrelizumab combined with albumin paclitaxel and carboplatin in treatment of advanced esophageal cancer
Objective To analyze the effect of camrelizumab combined with albumin paclitaxel and carboplatin in treatment of advanced esophageal cancer.Methods Patients(96 cases)with advanced esophageal cancer in the First Affiliated Hospital of Anhui Medical University from January 2020 to October 2021 were divided into control group(48 cases)and treatment group(48 cases)by random drawing.Patients in the control group were iv administered with Paclitaxel for injection(Albumin Bound)and Carboplatin Injection.Paclitaxel for injection(Albumin Bound)was given intravenously on the 1st and 8th day,and Carboplatin Injection was injected intravenously at 125 mg/m2;on the 1st day,200—400 mg/m2.The treatment group were iv administered with Camrelizumab for injection on the basis of the control group,200 mg/times on the first day,once every 3 weeks.A cycle had 21 days,and patients in two groups were treated for 2 cycles.After treatment,the clinical evaluations were evaluated,the progression-free survival,immune function indexes,tumor markers,serum inflammatory factor levels,and the levels of PD-L1 and dMMR in two groups before and after treatment were compared.Results After treatment,the 24-month PFS rate,OS,ORR,DCR,and TTP in the treatment group were significantly higher than those in the control group(P<0.05).After treatment,the levels of T total,Th,Th/Ts,NK,DC and DC/PBMC were significantly increased,while the levels of inhibitory Ts,CA19-9,CEA,CYFRA21-1,SCC-Ag,TNF-α and IL-8 were significantly decreased in the treatment group in two groups(P<0.05),and the level of these indexes in the treatment group was significantly better than that in the control group(P<0.05).After treatment,the level of PD-L1 was decreased and the level of PD-L1+/dMMR was increased in the treatment group,and the level of PD-L1 was decreased and the proportion of PD-L1+/dMMR was increased in the group with good prognosis(P<0.05).Conclusion Camrelizumab combined with albumin paclitaxel and carboplatin in treatment of advanced esophageal cancer can improve the level of tumor markers,inhibit inflammatory response,enhance immune function and improve the survival rate of patients with advanced esophageal squamous cell carcinoma.
Camrelizumab for injectionPaclitaxel for injection(Albumin Bound)Carboplatin Injectionadvanced esophageal squamous cell carcinomaPD-L1dMMRimmune function
NETL
NSTL
万方数据
